These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 14676171)

  • 1. Correct carboplatin dose?
    Loughner J
    Arch Otolaryngol Head Neck Surg; 2003 Dec; 129(12):1351; author reply 1351. PubMed ID: 14676171
    [No Abstract]   [Full Text] [Related]  

  • 2. Dose-banding of carboplatin: rationale and proposed banding scheme.
    Kaestner S; Sewell G
    J Oncol Pharm Pract; 2007 Jun; 13(2):109-17. PubMed ID: 17873111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose individualization of carboplatin after a 120-hour infusion schedule: higher dose intensity but fewer toxicities.
    Mercier C; Ciccolini J; Pourroy B; Fanciullino R; Duffaud F; Digue L; Tranchand B; Monjanel-Mouterde S; Guillet P; Nicoara A; Baciuchka M; Bagarry-Liegey D; Lacarelle B; Noble A; Durand A; Favre R
    Ther Drug Monit; 2006 Apr; 28(2):212-8. PubMed ID: 16628133
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma.
    Picton SV; Keeble J; Holden V; Errington J; Boddy AV; Veal GJ
    Cancer Chemother Pharmacol; 2009 Mar; 63(4):749-52. PubMed ID: 18607591
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin dosing in children: calculation by different formulae.
    Würthwein G; Krefeld B; Gerss J; Boos J
    Onkologie; 2011; 34(1-2):16-22. PubMed ID: 21346380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
    de Jonge ME; Huitema AD; Tukker AC; van Dam SM; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2005 Jan; 11(1):273-83. PubMed ID: 15671556
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
    de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
    Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I trial defining the maximum tolerated systemic exposure of topotecan in combination with Carboplatin and Etoposide in extensive stage small cell lung cancer.
    Gillenwater HH; McCune JS; Lindley C; Faucette S; Shord S; Donahue A; Socinski MA; Stewart CF; Zamboni WC; Kirstein MN; Moore D
    Cancer Invest; 2005; 23(6):511-9. PubMed ID: 16203659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carboplatin therapeutic monitoring in preterm and full-term neonates.
    Veal GJ; Errington J; Hayden J; Hobin D; Murphy D; Dommett RM; Tweddle DA; Jenkinson H; Picton S
    Eur J Cancer; 2015 Sep; 51(14):2022-30. PubMed ID: 26232270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
    Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies.
    Plummer R; Woll P; Fyfe D; Boddy AV; Griffin M; Hewitt P; Carmichael J; Namouni F; Cohen M; Verrill M
    Clin Cancer Res; 2008 Dec; 14(24):8288-94. PubMed ID: 19088046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intraperitoneal and intrathoracic administration of hydroxyapatite-carboplatin (HAp-CBDCA)].
    Mohri N; Mizuno I; Akamo Y; Takeyama H; Manabe T
    Gan To Kagaku Ryoho; 1999 Oct; 26(12):1791-3. PubMed ID: 10560396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dosage individualization of carboplatin and etoposide based on pharmacokinetic investigations.
    Jaehde U
    Int J Clin Pharmacol Ther; 1997 Feb; 35(2):76-8. PubMed ID: 9147713
    [No Abstract]   [Full Text] [Related]  

  • 15. [Optimizing the dosage].
    Heinzl S
    Med Monatsschr Pharm; 1997 Jan; 20(1):1. PubMed ID: 9082153
    [No Abstract]   [Full Text] [Related]  

  • 16. Toxicity profile of delayed high dose sodium thiosulfate in children treated with carboplatin in conjunction with blood-brain-barrier disruption.
    Neuwelt EA; Gilmer-Knight K; Lacy C; Nicholson HS; Kraemer DF; Doolittle ND; Hornig GW; Muldoon LL
    Pediatr Blood Cancer; 2006 Aug; 47(2):174-82. PubMed ID: 16086410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I study of G3139, a bcl-2 antisense oligonucleotide, combined with carboplatin and etoposide in patients with small-cell lung cancer.
    Rudin CM; Kozloff M; Hoffman PC; Edelman MJ; Karnauskas R; Tomek R; Szeto L; Vokes EE
    J Clin Oncol; 2004 Mar; 22(6):1110-7. PubMed ID: 15020613
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Weekly carboplatin as a strategy to prevent severe treatment-related emesis.
    Markman M; Kulp B; Peterson G; Kennedy A
    Gynecol Oncol; 2000 Aug; 78(2):265. PubMed ID: 10926818
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparative randomized trial of intermittent intrahepatic arterial carboplatin- versus doxorubicin-lipiodol emulsion in advanced hepatocellular carcinoma (stage IV).
    Homma H; Mezawa S; Doi T; Miyanishi K; Takada K; Kukitsu T; Oku T; Masuko E; Nojiri S; Niitsu Y
    Hepatogastroenterology; 2004; 51(58):1135-9. PubMed ID: 15239261
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
    Boss DS; Siegel-Lakhai WS; van Egmond-Schoemaker NE; Pluim D; Rosing H; Ten Bokkel Huinink WW; Beijnen JH; Schellens JH
    Clin Cancer Res; 2009 Jul; 15(13):4475-83. PubMed ID: 19531625
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.